The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
Zhejiang Da Xue Xue Bao Yi Xue Ban.
2023 Apr 25; 52(2): 162–168.
Language:
Chinese
|
English
治疗良性前列腺增生的六种新微创手术
Six novel minimally invasive therapies for benign prostatic hyperplasia
and
牛 鑫洋
浙江大学医学院附属第一医院泌尿外科, ，浙江
310003
刘 犇
浙江大学医学院附属第一医院泌尿外科, ，浙江
患者接受程度更高，但有
辐射暴露风险
前列腺水蒸气消融稍差短短短—前列腺高能水切割术相似短短短出血风险较高临时植入式镍钛装置差短—短至少两次入院前列腺支架差短短短被迫移除率高，新进展少
今后，BPH微创治疗方案应朝以下目标努力：①能够在局部麻醉下进行门诊手术；②手术效果能兼顾症状缓解和性功能、尿控功能的持久保护；③术后并发症更少、生活质量更好；④手术有更好的效价比等。从患者的角度，良好的微创治疗方案具有耐受性好、快速持久地缓解症状、恢复时间短、不良事件少、价格适中等特点；从医生的角度，良好的微创治疗方案需要具备能够局部麻醉门诊手术、学习曲线短、低风险、适用面广等特点
［
3
］
。相信微创治疗方案未来将更加人性化、精准化、智能化，拥有广阔的应用前景。
［缩略语］
良性前列腺增生（benign prostatic hyperplasia，BPH）；美国泌尿外科协会（American Urological Association，AUA）；下尿路症状（lower urinary tract symptoms，LUTS）；国际前列腺症状评分（international prostate symptom score，I-PSS）；经尿道前列腺电切术（transurethral resection of prostate，TURP）；微创前列腺悬扩术（prostatic urethral lift，PUL）；前列腺动脉栓塞（prostatic artery embolization，PAE）；前列腺水蒸气消融（water vapor thermal therapy，WVTT）；临时植入式镍钛装置（temporary implantable nitinol device，TIND）；欧洲泌尿外科学会（European Association of Urology，EAU）
Conflict of Interests
The authors declare that there is no conflict of interests
参考文献
1.
LERNER L B, MCVARY K T, BARRY M J, et al..
Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART Ⅰ, initial work-up and medical management
[J].
J Urol
, 2021,
206
(
4
): 806-817. 10.1097/ju.0000000000002231 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
2.
EGAN K B.
The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates
[J].
Urol Clin North Am
, 2016,
43
(
3
): 289-297. 10.1016/j.ucl.2016.04.001 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
3.
LERNER L B, MCVARY K T, BARRY M J, et al..
Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART Ⅱ-surgical evaluation and treatment
[J].
J Urol
, 2021,
206
(
4
): 818-826. 10.1097/ju.0000000000002184 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
4.
VARKARAKIS I, KYRIAKAKIS Z, DELIS A, et al..
Long-term results of open transvesical prostatectomy from a contemporary series of patients
[J].
Urology
, 2004,
64
(
2
): 306-310. 10.1016/j.urology.2004.03.033 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
6.
FRANCO J V, JUNG J H, IMAMURA M, et al..
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis
[J].
Cochrane Database Syst Rev
, 2021,
7
(
7
): CD013656.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
7.
ABT D, MÜLLHAUPT G, HECHELHAMMER L, et al..
Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial
[J].
Eur Urol
, 2021,
80
(
1
): 34-42. 10.1016/j.eururo.2021.02.008 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
8.
MCNICHOLAS T A.
Benign prostatic hyperplasia and new treatment options—a critical appraisal of the UroLift system
[J].
Med Devices (Auckl)
, 2016,
9
: 115-123. 10.2147/mder.s60780
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
9.
WOO H H, CHIN P T, MCNICHOLAS T A, et al..
Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
[J].
BJU Int
, 2011,
108
(
1
): 82-88. 10.1111/j.1464-410x.2011.10342.x [
PubMed
] [
CrossRef
]
[
Google Scholar
]
10.
DELONGCHAMPS N B, ZERBIB M.
Words of wisdom. Re: Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia
[J].
Eur Urol
, 2012,
62
(
2
): 350-351. 10.1016/j.eururo.2012.05.028 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
11.
GRATZKE C, BARBER N, SPEAKMAN M J, et al..
Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study
[J].
BJU Int
, 2017,
119
(
5
): 767-775. 10.1111/bju.13714 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
12.
RUKSTALIS D, GRIER D, STROUP S P, et al..
Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study
[J].
Pro-state Cancer Prostatic Dis
, 2019,
22
(
3
): 411-419. 10.1038/s41391-018-0118-x
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
13.
DEMERITT J S, ELMASRI F F, ESPOSITO M P, et al..
Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization
[J].
J Vasc Interv Radiol
, 2000,
11
(
6
): 767-770. 10.1016/s1051-0443(07)61638-8 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
14.
THEURICH A T, LEISTRITZ L, LEUCHT K, et al..
Influence of prostate artery embolization on different qualities of lower urinary tract symptoms due to benign prostatic obstruction
[J].
Eur Urol Focus
, 2022,
8
(
5
): 1323-1330. 10.1016/j.euf.2022.01.011 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
15.
CARNEVALE F C, MOREIRA A M, DE ASSIS A M, et al..
Prostatic artery embolization for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: 10 years’ experience
[J].
Radiology
, 2020,
296
(
2
): 444-451. 10.1148/radiol.2020191249 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
16.
ABT D, LYATOSHINSKY P, SCHMID H P, et al..
Prostatic artery embolisation: do we still need it and for whom?
[J].
Eur Urol Focus
, 2022,
8
(
2
): 384-387. 10.1016/j.euf.2022.04.005 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
ABT D, HECHELHAMMER L, MÜLLHAUPT G, et al..
Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial
[J].
BMJ
, 2018,
361
: k2338. 10.1136/bmj.k2338
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
18.
TAPPING C R, MACDONALD A, HADI M, et al..
Prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH) with haematuria in the absence of an upper urinary tract pathology
[J].
Cardiovasc Intervent Radiol
, 2018,
41
(
8
): 1160-1164. 10.1007/s00270-018-1941-0 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
WOO H H, GONZALEZ R R.
Perspective on the Rezūm
®
system: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy
[J].
Med Devices
, 2017,
10
: 71-80. 10.2147/mder.s135378
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
20.
MCVARY K T, GANGE S N, GITTELMAN M C, et al..
Response and rebuttal to editorial commentary on “Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study”
[J].
J Sex Med
, 2016,
13
(
6
): 936-937. 10.1016/j.jsxm.2016.05.002 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
21.
MCVARY K T, ROGERS T, ROEHRBORN C G.
Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyper-plasia: 4-year results from randomized controlled study
[J].
Urology
, 2019,
126
: 171-179. 10.1016/j.urology.2018.12.041 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
22.
MOLLENGARDEN D, GOLDBERG K, WONG D, et al..
Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience
[J].
Prostate Cancer Prostatic Dis
, 2018,
21
(
3
): 379-385. 10.1038/s41391-017-0022-9 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
23.
EREDICS K, MEYER C, GSCHLIESSER T, et al..
Can a simple geriatric assessment predict the outcome of TURP?
[J].
Urol Int
, 2020,
104
(
5-6
): 367-372. 10.1159/000506717 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
24.
GILLING P, BARBER N, BIDAIR M, et al..
Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial
[J].
Can J Urol
, 2020,
27
(
1
): 10072-10079. [
PubMed
]
[
Google Scholar
]
25.
GILLING P, BARBER N, BIDAIR M, et al..
WATER: a double-blind, randomized, controlled trial of Aqua-blation
®
vs transurethral resection of the prostate in benign prostatic hyperplasia
[J].
J Urol
, 2018,
199
(
5
): 1252-1261. 10.1016/j.juro.2017.12.065 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
26.
ASSAD A, NGUYEN D D, BARBER N, et al..
WATER vs WATER Ⅱ 3-year update: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 cc and 80-150 cc prostates
[J].
Urology
, 2022,
165
: 268-274. 10.1016/j.urology.2022.04.004 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
27.
GILLING P J, BARBER N, BIDAIR M, et al..
Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH
[J].
Can J Urol
, 2022,
29
(
1
): 10960-10968. [
PubMed
]
[
Google Scholar
]
28.
PROBST P, DESAI M.
Expectations facing reality: complication management after Aquablation treatment for lower urinary tract symptoms
[J].
Eur Urol Focus
, 2022,
8
(
6
): 1733-1735. 10.1016/j.euf.2022.04.013 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
29.
AMPARORE D, DE CILLIS S, VOLPI G, et al..
First- and second-generation temporary implantable nitinol devices as minimally invasive treatments for BPH-related LUTS: systematic review of the literature
[J].
Curr Urol Rep
, 2019,
20
(
8
): 47. 10.1007/s11934-019-0912-6 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
30.
PORPIGLIA F, FIORI C, BERTOLO R, et al..
3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction
[J].
BJU Int
, 2018,
122
(
1
): 106-112. 10.1111/bju.14141 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
31.
CHUGHTAI B, ELTERMAN D, SHORE N, et al..
The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, rando-mized, controlled trial
[J].
Urology
, 2021,
153
: 270-276. 10.1016/j.urology.2020.12.022 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
32.
AMPARORE D, FIORI C, VALERIO M, et al..
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction
[J].
Prostate Cancer Prostatic Dis
, 2021,
24
(
2
): 349-357. 10.1038/s41391-020-00281-5 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
33.
FABIAN K M.
The intra-prostatic “partial catheter” (urological spiral) (author’s transl)
[J].
Urologe A
, 1980,
19
(
4
): 236-238. [
PubMed
]
[
Google Scholar
]
34.
NG B, CHUNG E.
A state-of-art review on the prese-rvation of sexual function among various minimally invasive surgical treatments for benign prostatic hyper-plasia: impact on erectile and ejaculatory domains
[J].
Investig Clin Urol
, 2021,
62
(
2
): 148-158. 10.4111/icu.20200392
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
35.
SETHI K, BOZIN M, JABANE T, et al..
Thermo-expandable prostatic stents for bladder outlet obstru-ction in the frail and elderly population: an underu-tilized procedure?
[J].
Investig Clin Urol
, 2017,
58
(
6
): 447-452. 10.4111/icu.2017.58.6.447
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
36.
YILDIZ G, BAHOUTH Z, HALACHMI S, et al..
Allium TPS—a new prostatic stent for the treatment of patients with benign prostatic obstruction: the first report
[J].
J Endourol
, 2016,
30
(
3
): 319-322. 10.1089/end.2015.0593 [
PubMed
] [
CrossRef
]
[
Google Scholar
]
Articles from
Journal of Zhejiang University (Medical Sciences)
are provided here courtesy of
Zhejiang University Press
